Off-the-Shelf CAR T-Cell Therapy Advances in Early Lymphoma Testing

Relapsed, aggressive B-cell non-Hodgkin lymphoma rarely waits out a multiweek manufacturing queue, and that gap has pushed drug developers toward allogeneic, “off-the-shelf” chimeric antigen receptor (CAR) T-cell therapies built in advance from healthy donor cells. One such candidate, the CD19-directed therapy CTX110, has now moved further through early-phase testing in this population, according to a report in Blood Advances.¹

An Access Bottleneck Behind the Push for Off-the-Shelf CAR T-Cell Therapy

The only CD19-directed CAR T-cell therapies approved to date are autologous, meaning each dose is manufactured from a patient's own T cells after leukapheresis. That process carries real costs beyond price, including manufacturing failures, the need for bridging therapy to control disease while cells are produced, and limited access outside centers equipped to perform leukapheresis. Patients whose lymphoma is progressing quickly may not have the weeks that process requires.

A systematic review and meta-analysis of trial and real-world data put the scale of that wait in context. Pooled median time from leukapheresis to infusion ranged from about 30 days for axicabtagene ciloleucel, the fastest of the approved autologous products, to more than 48 days for tisagenlecleucel.² Allogeneic products such as CTX110 are manufactured in advance from healthy donor cells rather than the patient's own, so treatment can begin almost as soon as a patient is confirmed eligible, without a bridging interval.

The present CARBON trial (NCT04035434) was an open-label, multicenter, single-arm phase 1/2 study.¹ It enrolled adults with relapsed or refractory B-cell non-Hodgkin lymphoma who had received at least 2 previous lines of therapy. Sixty-three patients received at least 1 infusion of CTX110 after standard lymphodepleting chemotherapy with fludarabine and cyclophosphamide. A dose-escalation phase (n = 32 patients) tested 4 ascending dose levels in a standard 3+3 design, and a cohort-expansion phase (n = 31 patients) tested a 2-infusion regimen at the highest dose level, given on days 1 and 35.

The population was heavily pretreated: 59% had primary refractory disease, 43% had received 3 or more previous lines of therapy, and 81% had stage III or IV disease at enrollment. Diffuse large B-cell lymphoma not otherwise specified was the most common subtype, present in 54% of patients. The trial's primary end points were the incidence of dose-limiting toxicities in dose escalation and objective response rate in cohort expansion.

Early Response, Safety, and Durability Signals

Among the 57 patients whose first infusion was at dose level 3 or higher, the objective response rate was 65% and the complete response rate was 39%. Of the 22 patients who achieved a complete response, 5 (23%) reported a complete response at data cutoff, after a median follow-up of 34 months (range, 15-50). A second CTX110 infusion on day 35 was associated with a longer duration of response than a single infusion (HR, 0.65), although response rates were similar between the 2 regimens.

“This study of a first-generation allogeneic CAR T-cell therapy with a positive benefit-risk profile provides the foundation for next-generation allogeneic CAR T-cell therapy, zugocabtagene geleucel (formerly CTX112),” the researchers wrote.

Safety findings were consistent with other CD19-directed CAR T-cell products. Cytokine release syndrome (CRS) occurred in 34 patients (54%), with only 2 cases graded 3 or higher, and immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 13% of patients, also with 2 severe cases. All CRS and ICANS cases resolved with standard management. The most common grade 3 or higher adverse events were neutropenia (59%) and anemia and thrombocytopenia (35% each), and serious adverse events, including CRS, ICANS, and febrile neutropenia, occurred in 32% of patients. No graft-versus-host disease was reported, addressing a central safety question for donor-derived cell therapy.

Early-Phase, Single-Arm Data With No Control Group

The authors were direct about the limits of these numbers, describing the study's small size, exploratory nature, and restricted patient population among its own stated limitations. This was a single-arm trial with no comparator group, so the response, CRS, and durability figures above are descriptive signals from 63 patients, not a head-to-head comparison with the autologous CAR T-cell products already on the market. The 23% durable complete response rate, in particular, rests on just 5 patients, too small a number to generalize to the broader relapsed or refractory non-Hodgkin lymphoma population. The trial itself has since closed, and its sponsor has moved on to a next-generation allogeneic candidate rather than advancing CTX110 as tested here.

Even with those caveats, the access argument is the part of this trial likely to matter soonest. If an allogeneic, off-the-shelf CD19 CAR T-cell product eventually clears pivotal testing, it could shorten the gap between a treatment decision and infusion for patients whose lymphoma cannot wait out a manufacturing queue, with downstream implications for how clinicians plan bridging care and how payers plan for timely authorization. That is a feasibility and access story so far, not a verdict on whether off-the-shelf CAR T-cell therapy can match the efficacy of its autologous predecessors.

References

1. McGuirk JP, Ghobadi A, Bachier CR, et al. Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood Adv. 2026;10(17):5778-5788. doi:10.1182/bloodadvances.2026020123

2. Locke FL, Hemmer MT, Kanters S, et al. Axicabtagene ciloleucel vein-to-vein time in trial or real-world settings vs other CAR T-cell therapies for relapsed/refractory large B-cell lymphoma: a systematic literature review and meta-analysis. HemaSphere. 2023;7(suppl 3):e7340170. doi:10.1097/01.HS9.0000971712.73401.70